Compare Bristol-Myers Squibb Co (BMY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Thomson Reuters Corp — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $116.30B), while Thomson Reuters Corp trades at $94.22 (market cap $39.67B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.9× Thomson Reuters Corp's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | TRI | |
|---|---|---|
Market Cap | $116.30B | $39.67B |
Sector | Health | Industrials |
52-Week High | $62.37 | $211.14 |
52-Week Low | $42.60 | $76.55 |
Enterprise Value | $152.24B | $41.62B |
Dividend Yield | 4.42% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Thomson Reuters (TRI) trades at $94.29, up 5.18% today, showing strong momentum near resistance at $95. The stock maintains solid fundamentals with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent developments include a joint venture with KKR and continued AI integration, positioning the company for growth in legal and professional markets.
The outlook is positive with a consensus price target of $129.96 implying 38% upside, supported by bullish analyst ratings (52% Buy). Key risks include execution of AI strategies and potential revenue pressures from market shifts. Institutional confidence remains high given stable cash flows and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
